Hutchison China Meditech Share Price (HCM)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Hutchison China Meditech	LSE:HCM	London	Ordinary Share	KYG4672N1016	ORD USD1

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-15.00p	-0.40%	3,725.00p	3,700.00p	3,750.00p	3,740.00p	3,725.00p	3,740.00p	2,633	15:47:45

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	175.0	-38.3	16.2	238.8	2,262.38

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Valirx (VAL), Port Erin (PEBI)

Hutchison China Meditech (HCM) Latest News

Hutchison China Meditech News

Date	Time	Source	Headline
22/8/2017	11:53	ALNC	DIRECTOR DEALINGS: Hutchison China MediTech Non-Executive Buys ADSs
22/8/2017	09:00	UKREG	Hutchison China Meditech Limited Director's Share Dealing
18/8/2017	10:50	UKREG	Hutchison China Meditech Limited Directors' Share Dealing
15/8/2017	10:30	UKREG	Hutchison China Meditech Limited Directors' Share Dealing
10/8/2017	12:20	ALNC	DIRECTOR DEALINGS: Hutchison China Non-Executive Lifts Stake
10/8/2017	09:35	UKREG	Hutchison China Meditech Limited Director's Share Dealing
07/8/2017	12:43	ALNC	DIRECTOR DEALINGS: Hutchison China Meditech Directors Lift Stakes
07/8/2017	09:45	UKREG	Hutchison China Meditech Limited Directors' Share Dealing
31/7/2017	08:54	ALNC	Hutchison China MediTech Keeps 2017 Guidance As Portfolio Develops
31/7/2017	07:11	ALNCF	Alliance News Flash Headline

More Hutchison China Meditech News

Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date	Time	Title	Posts
22/8/2017	12:08	(Chi-Med)Hutchinson China Meditech Limited	994
13/6/2017	07:54	Hutchison China Meditech- CHARTS AND DISCUSSION	74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2017-08-23 16:12:16	3,725.00	100	3,725.00	O
2017-08-23 15:55:03	3,750.00	1,000	37,500.00	OK
2017-08-23 15:38:15	3,741.87	100	3,741.87	O
2017-08-23 15:37:35	3,740.00	500	18,700.00	O
2017-08-23 15:33:31	3,730.00	500	18,650.00	O

View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Date	Subject
23/8/2017 09:20	Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 3,740p. Hutchison China Meditech has a 4 week average price of 3,375p and a 12 week average price of 3,055p. The 1 year high share price is 4,055p while the 1 year low share price is currently 1,782.50p. There are currently 60,735,104 shares in issue and the average daily traded volume is 12,006 shares. The market capitalisation of Hutchison China Meditech is £2,262,382,624. Read Full Thread Reply
15/8/2017 11:59	mad foetus: More director buys. I tried a cheeky top up online but none available. Await the inevitable news and a £50 share price over the next couple of months Read Full Thread Follow Reply
04/8/2017 18:17	nerdofsteel: I agree dbadvn although for me price swings are irrelevant as I've been invested and have been building a position for 10 years and will continue for the next 10 years. 2000% in the last 10 years has demonstrated that, over the long term, the Company delivers. I agree with your point about NASDAQ and US Analysts, as that is what is controlling the share price. The London listing is now irrelevant and I can see a time when they de-list as it serves no real purpose at all. Read Full Thread Follow Reply
03/8/2017 09:34	nerdofsteel: Growth over the last 10 years has been astonishing and Simon To is right to state “Chi-Med’;s consistent strategy over the past 16 years has generated considerable shareholder value" - to the tune of 2000% However, I think he is also right to suggest that if you think that is astonishing, you ain't seen nothing yet! The CEO said recently they were working on 2 or 3 big things any one of which will radically change 2017 guidance. That suggests a major Big Pharma licencing deal is on the cards like the recent Beigene/Celgene one announced 2 weeks ago, prompting Beigene's share price to go up 75% Read Full Thread Follow Reply
13/7/2017 08:10	nerdofsteel: https://seekingalpha.com/article/4087275-chinese-oncology-company-great-potential?auth_param=1dk0ei:1cmclhp:1f288d3bb15c78e187ced953dcba7e21&uprof=45&dr=1 "The relative ignorance in the US about the company’s potential makes it a great investment right now" This article offers a great perspective for those looking to invest for the long term, and by that I mean 5 years + And it is the U.S share price that mainly drives the UK share price now, as volumes are usually bigger on NASDAQ Read Full Thread Follow Reply
07/3/2017 16:46	storm8: There is an article in tonight's London Evening Standard confirming the progress Chi Med have made and the Phase III trials of the cancer drug Fruquintinib, and probably one of the drivers for the >3% rise in share price today. I hold and will continue to do so. Read Full Thread Follow Reply
20/12/2016 12:02	hamsterdam: Yeah, thought it would have moved the share price a little though Read Full Thread Follow Reply
07/12/2016 10:11	nerdofsteel: The LSE share price tanked because the NASDAQ IPO (2 x ADR's per AIM Ordinary share) was priced below what was originally expected, presumably because the Institutions taking up the offer wouldn't pay the full price. The effect was the London share price tanked overnight. Now Institutions are starting to buy on NASDAQ, because they can see exactly how valuable the pipeline is and that this Company is unique in the Biotech space eg. it actually generates cash. The bb is quiet because there are very very few Private Investors, most are instutions (it is Mark Slater's largest holding in his growth fund. CK Hutchison hold 60%. IMO most private Investors do not invest because drug development is a very very long term game. However, after 14 years we have our first drugs coming to the market next year and these will be Blockbusters with peak annual sales potential of $100's millions Looking at the sales forecasts, using standard valuations of P/E, P/S, nett margis etc it is my view we will have a mcap in excess of $10bn within the next 5-10 years Read Full Thread Follow Reply
04/12/2016 16:41	nerdofsteel: Thanks Steeplejack, I noticed that I have a model which uses a range of criteria to value the Company based on blended Biotech and Pharmaceutical averages of P/E, P/S and nett margins, amongst other metrics. Based in what is a very conservative revenue number of $657m, which assumes Savolitinib and Frquinitinib get BT for certain targets and only achieve 50% of forecast peak sales my valuation figures are:- 2020 Revs $657,000,000 EPS $1.56 P/S 10.92 mcap $5,902,845,408 ADR Price $48.66 Ordinary share price £76.63 (2 x ADR) Moving from 2020 towards 2025 and 2030 the figures become even more interesting. The only thing that may hold back some U.S. Institutional Investors is that there's little if any chance of the Company being taken over, unlike small U.S Biotech's that often get a single drug or a couple of drugs to market then get swallowed up by a major player (Baxalta is a great example) Read Full Thread Follow Reply
02/12/2016 10:52	steeplejack: Written up in latest IC -In our view, the high potential of the clinical pipeline makes Chi-Med a very attractive investment proposition and recent share price weakness offers an excellent entry point. Plus, as the group closes in on commercial launch it is likely to grab the attention of more biotech-savvy US investors and that could drive the price up further. Buy.Investors Chronicle 2 Dec Read Full Thread Follow Reply
17/3/2016 07:34	steeplejack: I think that explains the sharp drop in share price some weeks back.The intended pricing of the ADSs must of leaked out.An equivalent London price of £19.42 is a sizeable discount to the existing AIM price.I'd be surprised if we didn't see a few taking a quick profit in the US.Maybe,it was optimistic but I thought (especially given you can get a slug of stock)they might get this placing away at nearer the AIM price ie £22-50 odd.Not to be.I can see them doing the greenshoe,additional placing,in full.Who the hell wouldn't want to go for that at a discount to the London price of getting on for 15%!Nonetheless,they've done the issue in a difficult environment and have a listing in the US which will no doubt prove to be the primary vehicle for any intended fund raising in future years (as it has proven for GWP). "7,500,000 ADSs were sold in the Offering at a price of US$13.50 per ADS, and the offering price is thus equivalent to approximately GBP19.42 per ordinary share (on the basis of an assumed exchange rate as quoted in the preliminary prospectus of GBP1.00 to US$1.39). Each ADS represents one-half of one ordinary share of Chi-Med. The ADSs have been approved for listing on the Nasdaq Global Select Market and are expected to begin trading on March 17, 2016 under the ticker symbol "HCM." Chi-Med's ordinary shares will continue to be traded on the AIM market of the London Stock Exchange following the Offering under the ticker symbol "HCM." Read Full Thread Follow Reply

Hutchison China Meditech share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:43 V: D:20170823 23:29:20